Mesothelioma remains difficult to detect at an early stage. Doctors therefore explore blood and fluid-based biomarkers. Three proteins receive special attention. These are mesothelin, fibulin-3 and osteopontin. Each offers useful information for diagnosis and monitoring.
Mesothelin appears in high amounts on mesothelioma cell surfaces. The body releases a soluble form into the blood. This form is called soluble mesothelin-related peptides. Blood tests can measure these levels. Elevated readings often support a mesothelioma diagnosis. Moreover, doctors use serial measurements to track disease progress or treatment response. However, mesothelin levels can also rise in other conditions. This reduces its specificity when used alone.
Fibulin-3 provides another promising signal. Researchers find higher concentrations of this protein in the blood and pleural fluid of mesothelioma patients. Studies show that fibulin-3 can help separate mesothelioma from other lung diseases. In addition, it may detect the disease earlier than some traditional methods. Its performance in pleural effusion samples looks especially useful. Therefore, many investigations continue to evaluate fibulin-3 as a supportive diagnostic tool.
Osteopontin also rises in patients with mesothelioma. This glycoprotein takes part in cell adhesion and inflammation. Blood tests can detect increased osteopontin levels. The marker shows potential for identifying disease presence. At the same time, osteopontin increases in several other cancers and inflammatory states. As a result, it lacks strong specificity on its own.
Doctors rarely rely on any single biomarker. Instead, they combine these markers with imaging and tissue examination. The three proteins together can improve diagnostic confidence. Furthermore, ongoing research aims to refine cut-off values and testing methods. Better panels may support earlier detection in high-risk groups such as people with past asbestos exposure.
In summary, mesothelin, fibulin-3 and osteopontin each contribute valuable data. They help clinicians assess the likelihood of mesothelioma. They also assist in disease monitoring. Continued studies will clarify their exact place in routine clinical practice.